Back

Cancer Variant Interpretation Group UK (CanVIG-UK): updates on an exemplar national subspecialty multidisciplinary network

Garrett, A.; Allen, S.; Rowlands, C. F.; Choi, S.; Durkie, M.; Burghel, G. J.; Robinson, R.; Callaway, A.; Field, J.; Frugtniet, B.; Palmer-Smith, S.; Grant, J.; Pagan, J.; McDevitt, T.; Hughes, L.; Johnston, E.; Yarram-Smith, L.; Logan, P.; Reed, L.; Snape, K.; Hanson, H.; McVeigh, T. P.; Turnbull, C.; CanVIG,

2026-03-19 genetic and genomic medicine
10.64898/2026.03.17.26348157 medRxiv
Show abstract

Cancer Variant Interpretation Group UK was established in 2017 in response to the publication of the 2015 ACMG/AMP v3 guidance for the interpretation of sequence variants. Its initial purpose was to ensure consistency in the UK clinical-laboratory community implementation of ACMG/AMP v3 guidance for cancer susceptibility genes (CSGs). Still convening for monthly national meetings, the remit of CanVIG-UK now encompasses additional activities delivered under the following objectives: O_LICreation of a national multidisciplinary professional network and regular forum. C_LIO_LIDelivery of training and education. C_LIO_LIEstablishment of a consensus approach to the fundamentals of variant interpretation in cancer susceptibility genes. C_LIO_LIDevelopment and ratification of gene-specific frameworks for variant interpretation for cancer susceptibility genes. C_LIO_LIDevelopment and maintenance of an online platform to facilitate information sharing and variant interpretation within the UK clinical-laboratory community. C_LIO_LIFacilitation of UK contribution to international variant interpretation endeavours. C_LI A survey of CanVIG-UK members evaluating the impact of these activities conducted in November 2025 had 163 responses, including 113 clinical scientists/trainees and 27 Clinical Genetics consultants/trainees. The utility of the CanVIG-UK consensus recommendations for variant interpretation in cancer susceptibility genes was highly rated, with 89/145=61.4% of survey respondents reporting using the guidance at least weekly ([≥]4 times/month) and 124/128=96.9% rating it as extremely/very useful. The usage frequency and utility of the gene-specific guidance reported by survey respondents were similar to those reported for the main consensus specification. Both qualitative and quantitative survey responses clearly demonstrate the value of the CanVIG-UK activities to the clinical-diagnostic community. Key messagesO_LIWhat is already known on this topic: Cancer Variant Interpretation Group UK (CanVIG-UK) is a national subspeciality multidisciplinary network first established in 2017. It brings together members of the UK clinical-laboratory community to improve accuracy and consistency in the interpretation of variants in cancer susceptibility genes (CSG) C_LIO_LIWhat this study adds: this article presents the results of a survey of CanVIG-UK members, demonstrating the impact of CanVIG-UK activities on their services, as well as a review of progress in the six updated objectives of CanVIG-UK C_LIO_LIHow this study might affect research, practice or policy: this article presents current priorities and practices and potential future directions for variant interpretation in CSGs across the UK and Republic of Ireland C_LI

Published in Journal of Medical Genetics (predicted rank #3) · training set

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.